Thalassaemia
-
NOVITÀ
-
NOVITÀ
TIF Releases New Scientific Bulletin To Highlight Research On Haemoglobin Disorders
A key objective of the Thalassaemia International Federation is to inform and update regularly the global haemoglobinopathies family, both patients and physicians, on the progress and new developments that arise…
Leggi di più » -
NOVITÀ
-
NOVITÀ
WHO SEAR Publishes Desk Review of Haemoglobinopathies in the South-East Asia Region
In an effort to understand the prevalence of thalassaemic syndromes and the existent blood supply system available within each country of the South-East Asia Region, the WHO Regional Office for…
Leggi di più » -
NOVITÀ
TIF Presents The Federation’s Annual Report For 2020
“Our commitment to unite the patient voice and to advocate at the highest possible levels for equal access to all treatment options remains our number one priority.“ TIF President –…
Leggi di più » -
NOVITÀ
Hemoglobin Disorders In Europe: A Systematic Effort Of Identifying And Addressing Unmet Needs And Challenges By TIF
The recent population movement has led to a steady increase of carriers and patients with haemoglobin disorders, namely thalassaemia and sickle cell disease, in all countries of the European Union.…
Leggi di più » -
NOVITÀ
Live Webinar on Thalassemia: Advances in 2021 with Dr M.D. Cappellini
The past decade has witnessed path-breaking advances with regard to novel therapeutic approaches of thalassaemia and, most significantly, phenomenal developments made in the direction of gene therapy of β- thalassaemia…
Leggi di più » -
NOVITÀ
Clinical Trials Update: The June 2021 Edition
TIF provides you with comprehensive and up-to-date information on developing drugs and therapies for thalassaemia and sickle cell disease (SCD) currently in clinical trials. Our most recent June 2021 update…
Leggi di più » -
NOVITÀ
TIF Is Actively Participating In The 26th EHA Annual Congress
TIF is excited to be participating in the 26th EHA Annual Congress, held this year virtually on 09 – 17 June 2021. Ms Lily Cannon, TIF Operations Manager, attended a…
Leggi di più » -
NOVITÀ
Bluebirdbio Announces The Lifting Of FDA Clinical Hold for Sickle Cell Disease And β-Thalassaemia Studies
bluebird bio, Inc. today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin…
Leggi di più »